You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Overall, GenMark's ePlex Respiratory Pathogen Panel 2 provides results for more than 20 viruses and bacteria, including SARS-CoV-2, flu A and B, RSV, and rhinovirus.
The firm said its ELISA multiplex SARS-CoV-2 test may enable early diagnosis of infected patients and broaden the number of testing options at the point of care.
The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.
A research team said the study provides some evidence that there is potential for saliva testing in broad surveillance of past exposure to SARS-CoV-2.
A Korean research team is developing a biosensor that boosted sensitivity by using low-cost fabrication to align high-density carbon nanotubes.
The firm said that its Verigene II multiplex system is on track to launch in mid-2020 among a number of new products scheduled for release this year.
The system showed good performance for cervical samples as well as orophyrengeal samples, and required no extraction step.
The diagnostic firms were the final companies in the coverage universe of 360Dx to present at the annual conference.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.